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The aim of the research was to study the relation between expression of Na+/I- symporter (NIS) in breast cancer (BC) of different 
molecular subtypes and sensitivity of BC cells to neoadjuvant chemotherapy (NACT) and to assess whether NIS expression may 
be used as a predictive marker of treatment efficacy. Materials and Methods: The study included 148 women with BC of stage II–III 
who were treated at the Precarpathian Clinical Oncology Center during 2012–2017. All patients were treated with NACT that in-
cluded 2–6 cycles of chemotherapy by FAC, AC scheme with 21 day intervals. NACT efficacy was evaluated every 2 cycles by mam-
mography according to RECIST criteria. Morphological and immunohistochemical study of NIS expression was performed by the 
standard methods on paraffin sections of surgically resected tumors. Results: The heterogeneity of different molecular BC subtypes 
regarding response to the NACT has been found. Her2/neu-positive and basal BC subtypes were the least susceptible to the NACT 
(p < 0.05). It was shown that NIS expression is related to the sensitivity of luminal B and basal BC subtypes to the NACT. The high-
est expression of NIS and impairment of its functional activity was registered in the group of patients with tumors resistant to NACT 
(stabilization of the disease or its progression) of luminal B (220 ± 8.6 points) and basal subtypes (290 ± 11.3 points) (p < 0.05). 
It was revealed that the disease-free survival of patients with BC of luminal B and basal subtypes was higher in the absence of NIS 
expression in tumor cells (p < 0.05). Conclusions: The results indicate that NIS can be used as an objective criterion for predicting the 
sensitivity of luminal B and basal BC subtypes to NACT, which will provide improved treatment outcomes in this group of patients.
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Breast cancer (BC) is the urgent problem of onco­
logy because of high rates of morbidity in female popu­
lation of many countries, including Ukraine [1]. In recent 
years, the prognosis of its clinical course has been 
based on determining the molecular subtypes of BC, 
namely luminal A, luminal B, basal or triple negative, 
HER2/neu­positive. It is accepted that these subtypes 
are characterized by different response to therapy, 
disease course and prognosis [2, 3].
Chemotherapy is one of the main treatments 
of BC patients used as a component of a combination 
therapy in neoadjuvant and/or adjuvant regimes. Che­
motherapy is of particular importance for treatment 
of luminal B and triple­negative (basal) BC subtypes, 
since these tumors are characterized by high prolifera­
tive activity and low survival rates of the patients [4, 5]. 
A significant barrier to effective treatment of BC, which 
globally is considered one of the most serious problems 
of modern oncology, is a natural or acquired resistance 
of tumors to chemotherapeutic drugs [6, 7]. Pre sently 
in clinical practice a number of prognostic indexes 
is used, but to date there are no universally accepted 
objective markers to predict an efficacy of neoadjuvant 
chemotherapy (NACT) in treating BC of different mo­
lecular subtypes. Thus, the problem of predicting the 
effectiveness of NACT in the treatment of BC patients 
is the lack of specific markers of sensitivity of tumors 
to the existing anticancer drugs.
In recent years, there have been the reports evidenc­
ing that the development of hormone­dependent malig­
nancies, including BC may be associated with impaired 
functional activity of the protein involved in the processes 
of iodine uptake by the cells: Na+/I– symporter (NIS). 
Under physiological conditions, this protein is expressed 
on the membrane of follicular cells of the thyroid gland [8, 
9]. When this protein is translocated from the membrane 
to the cytoplasm, which is observed in certain pathologi­
cal conditions, it loses its functional activity and does not 
provide iodine absorption by the cells from the microcir­
culation [10]. According to the data of the literature [8, 
9], under normal state and conditions of physiological 
balance in the cells of the mammary gland NIS expres­
sion is absent. It is shown that NIS expression is observed 
in more than 50% of malignant breast tumors [11]. There 
are data on the correlation between NIS expression with 
some biological features of malignant breast tumors such 
as receptor status and proliferative activity [12]. Proofs 
of the latter are the results of our previous studies, ac­
cording to which the most high rates of NIS expression 
and its malfunction is determined in cells with a high 
degree of malignancy and low sensitivity to doxorubi­
cin [13]. The above mentioned data allow consider that 
it is reasonable to study NIS expression in tumor cells 
of patients with BC of different molecular subtypes 
to clarify its impact in drug resistance.
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The aim of the research was to study the relation 
between expression of NIS and sensitivity of BC of dif­
ferent molecular subtypes to NACT and to assess 
whether NIS expression may be used as a predictive 
marker of treatment efficacy.
MATERIALS ANd METHOdS
Patients. The study included 148 women with 
BC stage II–III treated at the Precarpathian Clinical Onco­
logy Center in 2012–2017. Tumor stage was determined 
according to the TNM classification (6th edition, 2002). 
The histological type of the resected tumors was veri­
fied upon morphological study (hematoxylin and eosin 
staining) according to the International Histological 
Classification of the World Health Organization (2006). 
All patients were treated with NACT. The course included 
2–6 cycles of chemotherapy by FAC, AC scheme with 
21 day­intervals. NACT efficacy was evaluated every 
2 cycles by mammography according to RECIST crite­
ria [14, 15]. All patients were informed and agreed to the 
use of biopsy material for research purposes.
Immunohistochemical study. Expression of NIS, 
estrogen receptors, progesterone, and proliferative 
activity marker (Ki­67) in tumor cells was studied 
on paraffin sections (4–5 microns) of biopsy material. 
As primary antibodies, mAbs specific for NIS (clone 
MA5–12308; Thermo Scientific, USA), estrogen recep­
tor (clone 1D5), progesterone receptor (clone PgR636) 
and Ki­67 (MIB­1 clone; DakoCytomation, Denmark) 
were used. To visualize the reaction, EnVision System 
kit (Dako LSAB2 system, Denmark) was used according 
to the manufacturer’s recommendations. The sections 
were stained with Mayer’s hematoxylin. The expres­
sion of NIS was evaluated by semiquantitative method. 
Analysis of the results was performed using optical 
microscopy (× 100, oil immersion) using the classical 
method of H­Score [16]: 
S = 1 • N1+ + 2 • N2+ + 3 • N3+, 
where S is H­Score index; N1+, N2+, N3+ — number 
of cells with low, medium and high expression. The 
end result of the calculation is expressed in points: 
50–100 points — low expression; 101–200 — medium 
expression; 201–300 points — high expression of NIS.
Statistical analysis. For the statistical analysis 
of the results of immunohistochemical studies, Statis­
tica 6.0 program was used. To assess the significance 
of the differences between the expression of markers 
and other clinical and pathological parameters Stu­
dent’s t­test was used. Assessment of survival was 
determined by Kaplan — Meier method. The difference 
between the curves was assessed using the log­rank­
test. The critical level of statistical significance was 
accepted at p < 0.05.
RESULTS ANd dISCUSSION
The clinical characteristics of 148 patients with 
BC of stage II–III are shown in Table 1. According 
to the clinical data, the age of patients ranged from 
28 to 72 years, mean age was 51.2 ± 6.4 years. The 
majority of patients (56.0%) were at menopause, men­
strual function was preserved in 44.0% of patients. The 
number of patients with BC of stage II was 67 (45.3%), 
BC of stage III — 81 patients (54.7%). Upon compre­
hensive examination (X­ray, ultrasound, laboratory) con­
ducted before treatment, metastases (N1–3) in regional 
lymph nodes were found in 113 patients (76.3%).
Table 1. Clinical characteristics of BC patients stage II–III
Index Number of patientsn %
Total number of patients 148 100
Age of patients (years)
Average 51.2 ± 6.4
Range 28–72
Menstrual function
Preserved 65 44.0
Menopause 83 56.0
BC stage by TNM
II 67 45.3
III 81 54.7
Metastases in regional lymph nodes (category N)
N0 35 23.7
N1–3 113 76.3
Morphology of BC
Infiltrative ductal carcinoma 111 75.0
Infiltrative lobular cancer 37 25.0
Differentiation grade of BC
G1 (high) 37 25.0
G2 (moderate) 72 48.6
G3 (low) 39 26.4
Molecular subtype of BC
Luminal А 68 45.9
Luminal B 32 21.6
Her2/neu-positive 14 9.5
Basal 34 23.0
The distribution of patients by histological type 
of BC showed that most patients had infiltrative duc­
tal carcinoma (75.0%) of moderate differentiation 
(48.6%). The greatest incidence was registered for 
luminal A subtype — 45.9%. Incidence of luminal B, 
Her2/neu­positive and basal subtypes of BC was 21.6; 
9.5 and 23.0% respectively.
Depending on the degree of clinical effect of NACT 
(according to RECIST criteria) all patients were distri­
buted into 2 groups. The 1st group included 71 BC pa­
tients who have demonstrated a positive response 
to the NACT: complete regression (CR) was observed 
in 11 patients, partial regression (PR) — in 60 patients. 
2nd group was formed of 77 women with BC resistant 
to the treatment, including 56 patients with stabilization 
of tumor growth and 21 patients with BC progression 
in the setting of NACT (Table 2).
Analysis of the treatment effectiveness among 
different molecular BC subtypes has revealed their 
heterogeneity regarding their response to the NACT. Ac­
cording to the data given in Table 2, most frequently the 
positive effect of the treatment was detected in patients 
with luminal A subtype: in 79.4% cases positive effect 
(CR (16.2%) or PR (63.2%)) was observed. In the group 
of BC patients with luminal B subtype stabilization of tu­
mor growth was observed in 71.9% cases and PR after 
the NACT — in 25% cases (Table 2). Her2/neu­positive 
and basal subtypes of BC showed the lowest sensitivity 
to NACT. As can be seen from the data (Table 2), PR was 
observed only in 14.2 and 20.6% of the investigated 
cases of Her2/neu­positive and basal BC subtypes, 
while in the rest of cases stabilization of the tumor 
growth or tumor progression were registered, indicating 
that NACT was ineffective (Table 2).
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Table 2. Efficacy of NCT in BC of different molecular subtypes
Molecular subtype of BC
Number of patients, n (%)
The clinical effect of NACT (the RECIST criteria)
CR PR Stabiliza-tion
Progres-
sion
Luminal А (n = 68) 11 (16.2) 43 (63.2)* 14 (20.6) 0
Luminal B (n = 32) 0 8 (25.0) 23 (71.9)* 1 (3.1)
Her2/neu-positive (n = 14) 0 2 (14.2) 6 (42.9) 6 (42.9)*
Basal (n = 34) 0 7 (20.6) 13 (38.2) 14 (41.2)*
Note: *р < 0.05 compared with other molecular subtypes.
At the next stage of the study, we have analyzed 
clinical effect of NACT depending on the level of NIS 
expression in BC (Fig. 1). As shown in Fig. 2, in the tis­
sue of luminal A and Her2/neu­positive subtypes either 
sensitive or resistant to NACT, expression of NIS was 
low (close to 100 points) compared with tumors of other 
molecular subtypes. In most tumors of BC patients with 
luminal B subtype who showed response to treatment, 
medium level of NIS expression (160 ± 7.8 points) was 
registered, while in BC patients with luminal B subtype 
who showed disease stabilization or tumor progression 
high level of NIS expression (220 ± 8.6 points) was 
detected (р < 0.05). The highest expression of NIS 
in tumor tissue was registered in the group of patients 
with basal BC (р < 0.05) (Fig. 2). Interestingly, in patients 
with basal BC subtype and the positive effect of the 
treatment the expression of NIS was 240 ± 7.6, while 
in patients with tumors resistant to NACT this index 
amounted to 290 ± 11.3 points (р < 0.05).
b
a
Fig. 1. Medium and high level of NIS expression in BC cells, im­
munohistochemical reaction, Meyer hematoxylin staining × 400
Since it is known that the NIS is capable to trans­
port iodine only if it is expressed on the membranes 
of cells [10], we examined the localization of this protein 
in the tissue of BC of different molecular subtypes and 
with different sensitivity to the NACT. As show the data 
presented in Fig. 3, in the cells of luminal A and Her2/
neu­positive BC subtypes NIS was expressed both 
on the membrane and in the cytoplasm, whereas in cells 
of luminal B and basal BC subtypes its localization was 
predominantly cytoplasmic (p < 0.05) (Fig. 3). The 
number of cells with membrane staining of NIS in lumi­
nal B and basal subtypes was 75 and 85%, respectively.
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Fig. 2. The level of NIS expression in tumor cells of patients with 
BC of different molecular subtypes depending on the clinical ef­
fect of NCT.  *р < 0.05 compared with other molecular subtypes; 
#p < 0.05 compared with sensitive tumors
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Fig. 3. Distribution of NIS expression in cells of different molecu­
lar subtypes of BC.  *р < 0.05 compared with other molecular 
subtypes
As far as NIS expression could be related to the 
sensitivity of luminal B and basal subtypes to the NACT, 
we analyzed the survival of patients considering the 
presence of this protein in tumor cells. It was shown 
(Fig. 4) that the disease­free survival of patients with 
BC of luminal B and basal subtypes was higher in the 
absence of NIS expression in tumor cells. Relapse 
in patients with BC of luminal B subtype positive for 
NIS expression was determined in 12% of patients, 
while in patients with basal subtype — in 31% cases.
Thus, the present study has shown a relation 
between NIS expression and response to the NACT 
in patients with BC of certain molecular subtypes. The 
highest expression of NIS and disturbance of its func­
tional activity was recorded in cells of luminal B and 
basal subtypes resistant to NACT. It was established 
that disease­free survival of patients with luminal B and 
basal BC subtypes is significantly more worse in the 
case of NIS expression in tumor cells.
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Fig. 4 Disease­free survival (Kaplan — Meier) of patients with 
BC of luminal B (a) and basal (b) subtypes depending on NIS 
expression in tumor tissue (long­rank test, p < 0.05)
The results indicate that NIS can be used as an ob­
jective criterion for determining the sensitivity of lumi­
nal B and basal BC subtypes to NACT, which will provide 
improved treatment outcomes in this group of patients.
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